Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, is set to present at the LifeSci Partners Precision Oncology Day on February 17, 2021. The presentation, led by CEO Mark Erlander, will focus on the company’s innovative cancer treatment, onvansertib, aimed at addressing high-need conditions like KRAS-mutated colorectal and pancreatic cancer. One-on-one meetings will also occur. A replay of the presentation will be available on their website post-event.
Cardiff Oncology (Nasdaq: CRDF) presented updated results from its Phase 2 trial targeting metastatic castrate-resistant prostate cancer (mCRPC) at the ASCO-GU symposium. The trial evaluated the combination of onvansertib, abiraterone, and prednisone, showing a significant increase in the disease control rate (DCR) from 29% to 63% when treatment days were optimized from 5 to 14. With 75% of patients in the optimized cohort achieving stable disease at 12 weeks, the trial appears poised to meet its primary endpoint of 30% DCR. The study's findings suggest potential for enhanced patient outcomes in this challenging cancer subtype.
Cardiff Oncology (Nasdaq: CRDF) announced FDA approval to begin a Phase 2 clinical trial for onvansertib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This trial will assess the combination of onvansertib, nanoliposomal irinotecan, leucovorin, and 5-FU as a second-line treatment for patients who failed prior gemcitabine therapy. Approximately 40 patients will be enrolled across six U.S. sites, including Mayo Clinic locations. The trial aims to evaluate safety and efficacy, with overall response rate as the primary endpoint.
On January 15, 2021, Cardiff Oncology (Nasdaq: CRDF) presented data on its investigational drug, onvansertib, at the ASCO-GI symposium. The Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC) confirmed the recommended Phase 2 dose at 15 mg/m2. Notable outcomes included a 42% partial response rate and 67% of patients showing durable responses lasting over 6 months. Initial findings from the Expanded Access Program mirrored these results, with 66% of patients demonstrating tumor shrinkage. The trial involves collaboration with prominent cancer centers.
Cardiff Oncology (Nasdaq: CRDF) announced the immediate resignation of Dr. Thomas Adams as Executive Chairman and Chairman of the Board, effective December 21, 2020. Dr. Rodney Markin has been appointed as the new Chairman. The board expressed gratitude for Dr. Adams' twelve years of leadership, which facilitated the company's transition from molecular diagnostics to drug development. With ongoing clinical programs targeting KRAS-mutated colorectal cancer, castration-resistant prostate cancer, and acute myeloid leukemia, the company aims to enhance treatment options for patients in need.
Cardiff Oncology (Nasdaq: CRDF) announced updated data from its Phase 1b/2 trial of onvansertib for relapsed/refractory acute myeloid leukemia (AML) at the 62nd ASH Annual Meeting. The oral presentation revealed that 20% of 45 patients achieved complete remission (CR/CRi), with 55% of responders having splicing factor mutations. Notably, the treatment showed promising safety and tolerability, with decreases in mutant ctDNA correlating with clinical responses. This data emphasizes onvansertib's potential impact in treating AML, addressing unmet medical needs.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on developing cancer treatments, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded fireside chat with the company's management will be available from November 23 to December 3. Additionally, Cardiff Oncology will conduct 1x1 meetings from December 1 to 3, requested exclusively through Piper Sandler. The company's investigational drug, onvansertib, targets multiple cancers, including KRAS-mutated colorectal cancer and castration-resistant prostate cancer.
Cardiff Oncology, Inc. (Nasdaq: CRDF) reported third quarter highlights and financial results for the period ending September 30, 2020. Key achievements include positive clinical data for onvansertib in treating KRAS-mutated colorectal cancer at the ESMO conference, showcasing a 91% disease control rate among participants. The company raised approximately $100 million from a public stock offering, enhancing its financial position for ongoing and new projects. As of September 30, it held $36.4 million in cash, with total operating expenses of $4.5 million for the quarter.
Cardiff Oncology (Nasdaq: CRDF) announced positive findings from its Phase 2 trial of onvansertib for metastatic castration-resistant prostate cancer (mCRPC) at the 27th Annual PCF Scientific Retreat. The trial showed that 31% of evaluable patients achieved disease control after 12 weeks, with a durable response noted in several cases. A gene signature biomarker was identified to predict patient response to the drug in combination with Zytiga® (abiraterone). Safety data indicated no significant issues across varying doses, reinforcing the potential of onvansertib to address drug resistance in mCRPC.
Cardiff Oncology, Inc. (Nasdaq: CRDF) has priced its underwritten public offering of 6,500,000 shares of common stock at $13.50 per share, aiming to raise approximately $88 million in gross proceeds. The offering is anticipated to close on or around October 2, 2020, pending customary conditions. Proceeds will be utilized for the clinical development of their drug candidate, onvansertib, alongside working capital and general corporate needs. Underwriters have a 30-day option to acquire an additional 975,000 shares at the offering price.